Collectively, poorer prognosis in cases with high PD-L1 expression in hormone therapy-naïve patients indicates the potential for improving outcomes in patients with PCa at a higher risk of recurrence, even before reaching the CRPC stage, by targeting the tumor immune response through PD-1/PD-L1 control. This evidence concerns the gene PDCD1 and neoplasm.